Clinical PipelineThe pipeline consists of 33 products in clinical development, with 8 in Phase 3 trials, providing potential upside.
Market ShareBrukinsa is believed to garner 55% of the global BTK inhibitor market at peak, potentially resulting in sales of $5.4B.
Revenue GrowthBrukinsa is on track to generate over $2B for the company, and total revenues are expected to reach $3.7B.